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In the present study we undertook an international postal survey to assess the current attitudes
towards the detection and management of hepatic metastases in colorectal cancer patients, who
have been operated on with curative intent. Results of this survey were compared to results ofan
earlier survey, held in 1985. Both surveys indicate that there is no consensus on the follow-up of
patients at risk of hepatic metastases. Especially the interpretation of unexplained rises in
carcinoembryonic antigen (CEA) levels leads to much controversy. Only 37% of the hospitals
performing liver surgery were willing to perform second-look laparotomies based on CEA only.
Also there is no agreement on the maximum number of liver metastases that will justify partial
liver resection for cure. Clearly, there is a need for prospective randomized trials on which a more
rational policy regarding hepatic metastases in colorectal cancer patients can be based.
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INTRODUCTION
Colorectal cancer is the second leading cause of death
from cancer 1. Although 75% of colorectal cancer pa-
tients will have a primary surgical resection for cure,
nearly half of all patients with colorectal cancer still die
ofmetastatic tumor2. Resection of liver metastases and
adjuvant chemotherapy are currently the most promis-
ing developments in the treatment of colorectal cancer
patients.
Because there exists worldwide controversy among
clinicians regarding optimal diagnostic and thera-
* Correspondence to: J. Kievit, M.D., Ph.D., Medical Decision
Making Unit, Building 43, Room 1.002, University Hospital Leiden,
P.O. Box. 9600, 2300 RC Leiden, The Netherlands, Telephone: NL-
71276780, Fax: NL-71225520.
peutic policies, we held in 1985 a postal survey of 290
hospitals in 13 Western countries 3. The response rate
was 98%, which is exceptionally high for a postal
survey. Nearly all hospitals in this survey used a sys-
tematic follow-up aimed at detecting liver metastases
in colorectal cancer patients operated for cure and
performed liver surgery when necessary. Approximate-
ly 75% of the hospitals treated patients with unresect-
able liver metastases with chemotherapy, and 33% of
the hospitals used adjuvant chemotherapy following
curative resection of liver metastases.
In 1992 we held, encouraged by our earlier results,
a second postal survey. We developed an extended
version of the 1985 questionnaire, which we sent to
1955 clinicians in 77 countries. Results of this survey
may give a more detailed and complete view on current
attitudes toward hepatic metastases.
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MATERIALS AND METHODS
In 1992 we sent a postal questionnaire to all 1955
members ofthe ’World Association ofHepato-Pancre-
ato-Biliary Surgery’. Addresses were obtained from the
1990 HPB membership registry.
The questionnaire consists of four parts:
(1) Detection of liver metastases by systematic fol-
low-up: Which diagnostic tests were used with
which frequency? Were diagnostic second-look
laparotomies performed?
(2) Resection of liver metastases: What was the
maximum number of metastases considered for
radical resection, and were they confined to one
or two lobes? How many patients were operated
for potentially resectable liver metastases in
1991, and in how many patients were liver meta-
stases actually resected? Which preoperative
imaging techniques were used to assess the
number ofliver metastases?Was the resectability
of liver metastases intraoperatively assessed us-
ing ultrasound imaging?
(3) Adjuvant chemotherapy following potentially
curative resection of colorectal cancer or partial
liver resection: Which drugs were administered
by which route?
(4) Chemotherapy of unresectable liver metastases:
How many patients were treated in 1991? By
which route were drugs administered?
A sample of the questionnaire is included in the
Appendix.
RESULTS
Response rate
The 1990 HPB membership registry listed 1955 names
and addresses of clinicians involved in the field of
hepatic, pancreatic and biliary surgery. Of these 1955
clinicians 903 were listed by their private address and
1052 by their hospital address. The 1052. clinicians
listed by their hospital address were employed in 653
different hospitals. Thus, in total, there were 1556
questionnaires sent.
Fifty-three of these questionnaires were returned to
us unopened, indicating that at least 3% of the ad-
dresses we used were incorrect.
A total of 171 questionnaires were answered and
returned to us. The 1992 questionnaire, however, was
sent to 77 countries worldwide, in contrast to the 1985
questionnaire, which was sent to 13 Western coun-
tries* only. The response rate of the recent survey
calculated for these 13 Western countries is 21%.
Detection of liver metastases
In the first section of the 1992 questionnaire we asked
clinicians to describe the follow-up they used for
colorectal cancer patients operated for cure. System-
atic routine follow-up was used in 150 (88%) of the
hospitals. Of these hospitals 134 (89%) used follow-up
schemes of five years or longer.
Scheduled history taking and physical examinations
were used in 144 (96%) hospitals, routine liver bio-
chemistry in 119 (79%), serum tumor markers in 141
(94%), liver ultrasonography in 111 (74%), and com-
puterized tomography (CT) in 65 (43%). The average
number of individual diagnostic tests per year are
presented in Table 1.
Serum carcinoembryonic fintigen (CEA) assays were
used by all 141 hospitals which used tumor markers.
Other serum tumor markers also used by these hospi-
tal were CA 19-9 (carbohydrate antigen associated
with gastrointestinal cancer) in 32 hospitals, AFP (al-
pha-fetoprotein) in 9 hospitals, TPA (tissue polypept-
ide antigen)in 4 hospitals, CA 50 (carbodydrate
antigen associated with carcinomas) in 3 hospitals, CA
125 (carbohydrate antigen associated with ovarian
cancer) in 2 hospitals, CA 195 (carbohydrate antigen
associated with gastrointestinal cancer) in 1 hospital,
ferritin in 1 hospital, and NCC-ST 439 (monoclonal
antibody against gastric cancer cells) also in 1 hospital.
Second-look laparotomies solely based on signifi-
cant and consecutive rises in CEA-levels were per-
formed in 52 (37%) of the 141 hospitals.
Compared to the 1958 survey, fewer hospitals per-
formed clinical evaluations and liver biochemistry tests
Table 1 Mean number of diagnostic tests per year used to detect
liver metastases
Diagnostic test Year offollow-up
Clinical evaluation 3 3 2 2 2
Liver biochemistry 3 2 2
Tumor markers 4 3 2 2 2
Liver ultrasonography 2 2
Liver CT
* Austria, Belgium, Canada, France, Germany, Israel, Italy, Spain,
Sweden, Switzerland, the Netherlands, the United Kingdom (UK),
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Table 2 Diagnostic tests used to detect liver metastases in 13 Western countries
Diagnostic test Percentage ofhospitals per country
France Germany The Netherlands UK USA and Other All
Canada
1985 Survey
Clinical evaluation 100 100 100 91 100 94 98.2
Liver biochemistry 88 95 96 59 90 88 87.3
Serum CEA 88 100 73 50 97 85 75.0
Imaging techniques 84 95 55 41 64 73 64.1
1992 Survey
Clinical evaluation 100 100 86 50 75 91 82.4
Liver biochemistry 75 91 50 42 68 85 70.6
Serum CEA 100 100 79 50 79 97 84.3
Imaging techniques 100 100 36 33 61 88 64.7
on a routine basis in 1991 (Table 2). Consequently,
serialCEA testing was the most frequently used screen-
ing method in colorectal cancer follow-up.
Resection of liver metastases
In the second section of the 1992 questionnaire we
asked about the surgical aspects of liver metastases. In
144 hospitals, in which numerical data on colorectal
cancer patients were available, liver metastases were
detected in 3250 patients in 1991. Potentially resectable
liver metastases were never considered for resection in
5 (3%) of the hospitals and were resected only when
solitary in28(16%) of the hospitals. In 81 (47%) of the
hospitals multiple metastases were resected when they
were confined to one lobe, with a maximum of 3 meta-
stases, while 57 (33%) of the hospitals also resected
multiple metastases not confined to one lobe, with
a maximum of 4 metastases. In 36 (21%) hospitals
resectability was assessed without a reference to the
number of metastases. In 1991 a total of 1238 (38%)
patients had surgery for liver metastases, and in 911
(74%) of these patients liver metastases were actually
resected.
When liver metastases were suspected, resectability
was assessed using preoperative imaging techniques.
Ultrasonography of the abdomen was used by 135
(82%) hospitals, CT (computerized tomography) by
112 (68%) hospitals, CT combined with angiography
in 103 (62%) hospitals, MRI (magnetic resonance
imaging) by 31 (19%) hospitals, and scintigraphy by
9 (5%) hospitals. The resectability of liver metastases
was assessed by intraoperative ultrasonography of the
liver in 85 (58%) of the hospitals which performed liver
resections in 1991. No increase in intraoperatively
di.agnosed unresectable recurrences was reported by
the hospitals which used this technique.
In comparison to the 1985 survey more hospitals
resected multiple bilobar metastases in 1991 (Table 3).
The number of liver resections per hospital has also
Table 3 Criteria for resection of liver metastases in 13 Western countries
Preoperative criteria Percentage ofhospitals per country
France Germany The Netherlands UK USA and
Canada
Other All
1985 Survey
No surgery 0
One solitary metastasis 20
Multiple unilobar metastases 64
Multiple bilobar metastases 16
1992 Survey
No surgery 0
One solitary metastasis 25
Multiple unilobar metastases 25
Multiple bilobar metastases 50
0 18 6 0
5 48 47 27
37 31 44 41
58 3 3 32
0 7 8 4
9 0 8 4
36 57 50 43
55 36 33 50
3
27
61
9
0
21
52
27
5.3
32.4
43.0
19.4
2.9
10.8
47.1
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Table 4 Mean number of partial liver resections per hospital per year in 13 Western countries
Survey Country
France Germany The Netherlands UK USA and Other All
Canada
1985 3 11 2 2 8 6 5.4
1992 21 28 3 4 15 7 11.5
increased (Table 4). Hospitals in the UK and the
Netherlands are less in favor of liver surgery, in con-
trast to hospitals in Germany, France, the USA and
Canada, which employ a more aggressive approach
towards liver metastases.
Adjuvant chemotherapy
The third part of the questionnaire surveys adjuvant
chemotherapy after resection of a primary tumor or
a recurrence. In 79 hospitals (46%) adjuvant chemo-
therapy was administered after a primary tumor resec-
tion for cure. Fluorouracil (5-FU) was administered in
66 (84%) of the hospitals using adjuvant chemother-
apy. Therefore it was the most frequently employed
chemotherapeutic drug given alone or combined with
other drugs. Combinations of 5-FU and levamisole
were used in 34 (43%) of the hospitals, and combina-
tions of 5-FU and folinic acid (leucovorin, citrovorum
factor) in 24 (30%). Other chemotherapeutic drugs
used were doxorubicin (Adriamycin, ADR), mitomycin
(MMC), cisplatin (CDDP), methotrexate (MTX),
fluorodeoxyuridine (FUdR), methylcyclohexylchloro-
ethylnitrosurea (methyl-CCNU), and interferon. In 62
(78%) of the hospitals systemic administration was
used to deliver adjuvant drugs to the patient. Hepatic
arterial infusion was employed by 4 (5%) and portal
venous infusion by 5 (6%) of the hospitals.
Adjuvant chemotherapy after resection for cure of
liver metastases was used in 49 (34%) of the hospitals
which performed partial liver resections in 1991. Ad-
ministrations of 5-FU with or without other chemo-
therapeuticdrugs were used in 38 (78%) of the hospi-
tals. The most frequently used combinations of 5-FU
were with levamisole in 11 (22%) and folinic acid in 14
(29%) of the hospitals. Other chemotherapeutic drugs
used were doxorubicin, farmorubicin, mitomycin, cis-
platin, methotrexate, fluorodeoxyuridine, interferon,
and interleukin 2. Systematic administrations were
used by 30 (61%), hepatic arterial infusion by 14 (29%)
and portal venous infusion by 2 (4%) of the hospitals.
Compared to the 1985 survey the overall use of
adjuvant chemotherapy has not changed in Western
countries (Table 5). Adjuvant therapy was used less in
Germany and the Netherlands, in contrast to France
and the UK where its use has increased.
Chemotherapy ofunresectable liver metastases
In the fourth and final part of the questionnaire we
asked about the use of chemotherapy in patients with
unresectable liver metastases. In the 144 hospitals men-
tioned earlier 2318 (71%) patients had unresectable
liver metastases, ofwhich 1172 (51%) were treated with
chemotherapy.
The number of hospitals using chemotherapy has
increased slightly compared to the 1985 survey (Table
6). This is mainly caused by an increase in the use of
chemotherapy in France and the UK. The average
number of patients treated with chemotherapy per
hospital, however, has dropped from 18 to 12 per year
(Table 7). In addition, a shift from local adminisatra-
tion towards systemic administration ofchemotherapy
was observed.
Table 5 Adjuvant chemotherapy after partial liver resections for cure in 13 Western countries
Adjuvant Percentage ofhospitals per country
chemotherapy
France Germany The Netherlands UK USA and
Canada
Other All
1985 Survey 24 47 9 9 47
1992 Survey 50 20 0 25 44
44
34
32.3
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Table 6 Chemotherapy of patients with unresectable liver metastases in 13 Western countries
Chemotherapy Percentage ofhospitals per country
France Germany The Netherlands UK USA and Other All
Canada
1985 Survey
Systemic 4 11 13 15 15 12 13.0
Local 36 53 15 21 43 42 33.8
Both 8 37 16 6 33 24 22.9
Other 4 0 3 3 6 6 4.2
Total 52 100 48 44 97 85 73.9
1992 Survey
Systemic 25 9 36 58 43 42 39.2
Local 0 9 7 8 14 12 10.8
Both 50 64 14 0 21 18 22.5
Other 25 0 0 17 0 9 5.9
Total 100 82 57 83 79 82 78.4
Table 7 Mean number of patients with unresectable liver metastases treated with chemotherapy per
hospital per year in 13 Western countries
Survey Country
France Germany The Netherlands UK USA and Other All
Canada
1985 15 34 10 12 20 15 18.0
1992 12 17 5 7 20 8 11.6
DISCUSSION
The present study was undertaken as a sequel to
a postal survey on attitudes toward detection and
management of hepatic metastases held in 1985 a. In
contrast to the 1985 survey, the recent survey had a low
response rate of only 21%. Several factors may have
contributed to this low response rate: (1) The extent of
the questionnaire. The recent questionnaire not only
contained more questions, but also asked more de-
tailed questions and assumed that data on the number
ofpatients with partial liver resections and chemother-
apy were available. (2) Satiety. Two other postal sur-
veys closely related to ours were held in 1992’’5. (3)
Incorrect addresses. In the recent survey, using the
1990 HPB membership registry, at least 3% of the
addresses were incorrect, compared to zero percent in
1985 survey.
Because only 171 questionnaireswere returned to us,
we decided against the use of inferential statistical
techniques. Therefore, only observed frequencies are
reported in this paper. Also, we feel it is inappropriate
to compare the 1985 and the recent surveys using
inferential statistics, because of the possible differences
between the two groups of respondents. The results of
the recent survey, however, could be of value in the
light of a worldwide discussion on colorectal cancer
follow-up, with special reference to the detection and
resection of hepatic metastases.
Our survey indicated that systematic routine follow-
up of colorectal cancer patients operated on with
curative intent was used.by 88% of the hospitals. The
majority of these hospitals used follow-up schemes of
five years or more. Scheduled history taking and physi-
cal examinations, routine liver biochemistry and car-
cinoembryonic antigen (CEA) monitoring were the
most popular and frequently used tests. Although there
is a National Institutes of Health (NIH) consensus
statement on the use of CEA [6], there still remains
controversy about the diagnostic and therapeutic pol-
icy following an unexplained rise in CEA. Only 37% of
the hospitals using CEA were willing to perform sec-
ond-look laparotomies based on significant and con-
secutive rises of CEA-levels only, as advocated by
Minton et al. 7 Alternatively, many hospitals may have
responded to such a rise by increasing the intensity of
follow-up.
The percentage of hospitals resecting liver meta-
stases in the 1992 survey has increased only slightly
compared to the 1985 survey. The number ofresections120 DAVID J BRUINVELS et al.
per hospital, however, has doubled from 6 to 12 resec-
tions per year. Also, the extent of liver operations has
increased. In the 1985 survey mainly solitary and
multiple unilobar liver metastases were resected, com-
pared to multiple unilobar and bilobar metastases in
the 1992 survey. The majority of the hospitals (79%)
regarded patients with more than 3 or 4 hepatic meta-
stases in the absence of extrahepatic disease as un-
resectable. This observation may give cause for
concern. Since the introduction ofmore sensitive imag-
ing techniques in recent years, smaller hepatic meta-
stases can be identified preoperatively. Approximately
70% of the hOspitals used extremely sensitive imaging
techniques like CT-angiography, CT-portography, or
MRI. The use of these recently developed techniques
would classify more patients as unresectable. Scheeles
proposed that resection to benefit prognosis seems
justified as long as complete tumor clearance can be
achieved, independent of number, distribution or size
of liver metastases. Therefore, the decision to resect
hepatic metastases should depend on the sensitivity of
the preoperative imaging techniques used, and not on
the application of maximum numbers found in the
literature [9, 10]. Intraoperative ultrasound should be
used to assess the resectability during the operation.
The additional value of this technique, however, re-
mains hypothetical. In our survey no increase in the
percentage of unresectable patients during operation
was observed when ultrasonography was used.
In less than half of the hospitals (46%) adjuvant
chemotherapy was administered following primary tu-
mor resection for cure. Adjuvant chemotherapy after
resection of hepatic metastases was used in 34% of the
hospitals which performed liver surgery. This may
indicate that the use of adjuvant chemotherapy is still
not very popular. Combinations offluorouracil (5-FU)
and levamisole with or without folinic acid (leucovorin,
citrovorum factor) were most frequently used, con-
forming to the NIH consensus statement on adjuvant
chemotherapy for colorectal cancer patients2. The ma-
jority of the hospitals used adjuvant chemotherapy
only when they collaborated in a clinical trial.
Patients with unresectable liver metastases received
chemotherapy in 78% of the hospitals. Over the last
years local chemotherapy has become less popular,
while systemic chemotherapy has gained in popularity.
Hospitals in the UK and the Netherlands make use
of less intensive follow-up compared with other West-
ern countries. Although the percentage of hospitals in
favor of liver surgery has increased according to our
recent survey in these two countries, a less aggressive
surgical attitude was found. Also per hospital less
patients were operated for liver metastases compared
to other countries. These findings are supported by the
results of postal surveys of Foster et al. and Karan-
jina et al.2 in England and Wales.
The results of our survey on the attitudes towards
detection and management of hepatic metastases of
colorectal origin indicate that there is no consensus on
the follow-up of colorectal cancer patients. The most
frequently applied diagnostic test in colorectal cancer
follow-up was serial CEA determinations. However,
the frequency of these determinations in the first years
after primary tumor resection was low in most hospi-
tals. Also, unexplained rises of CEA-levels were not
followed by second-look laparotomies in the majority
of the hospitals. Therefore, the current use of CEA-
testing is questionable. Another matter on which no
agreement is found, is the maximum number of liver
metastases justifying partiai liver resection. There may
be an increasing awareness that resection criteria
should not be limited to a fixed number metastases, but
should be based on the probability of ensuring free
surgical margins. Finally, there is consensus on the use
and type of adjuvant chemotherapy in colorectal can-
cer patients. However, most hospitals do not offer this
on a routine basis to their patients.
In conclusion, this survey indicates that there is
much need for prospective randomized trials on which
worldwide consensus can be reached regarding detec-
tion and management ofhepatic metastases ofcolorec-
tal origin.
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APPENDIX
2r’’ QUESTIONNAIRE ON LIVER METASTASES TREATMENT
POLICY OF COLORECTAL ORIGIN
Detection
1. Did your department use a SYSTEMATIC follow-up aimed at detecting liver
metastases in patients operated with curative intent for colorectal cancer in 1991?
If yes, please mark the appropriate boxes in the table below.
Months 12 15 18 21 24 27 30 33 36 39 42 45 48
Clinical Evaluation
Routine Liver Biochemistry
Liver Ultrasound
Liver CT
2. Was CEA ASSAY also part of a systematic follow-up aimed at detecting liver
metastases in 1991?
If yes, please specify the frequencies ofCEA assaysin st, 2nd, 3rd, 4th, and 5
th year
3. Are you willing to perform second look laparotomy on the basis of elevated
CEA ONLY (without any additional evidence on the presence of liver metastases by
other diagnostic tests)?
4. Did you use OTHER TUMOUR MARKERS in the systematic follow-up aimed at
detecting liver metastases in 1991?
If yes, which tumour markers did you use?
Please specify the frequencies of tumour marker detections in 1st, 2nd, 3rd, 4th, and 5
th
year.
II Surgery
1. In how many patients were liver metastases detected in 1991?
2. IfPOTENTIALLY resectable liver metastases were detected, what were your criteria
for considering surgery in 1991?
a. Never consider surgery (= continue with section III)
b. One solitary metastasis only
c. Multiple metastases confined to one lobe (please specify how many)
d. Multiple metastases not confined to one lobe (please specify how many)
3. When you suspected the presence of liver metastases, by what means did you PRE-
OPERATIVELY assess their resectability? (more than one item is allowed)
a. Ultrasound Imaging
b. Computerized Tomography
c. Computerized Tomography with Angiography
d. Magnetic Resonance Imaging
e. Scintigraphy
Yes
VqNo
51 54 57 60
Yes
U]No
Yes
No
Yes
U]No
pts.122 DAVID J BRUINVELS et al.
III
IV
4. How many patients underwent surgery for potentially resectable liver metastases
in 1991?
5. In how many of these patients were liver metastases actually resected?
6. Did you INTRAOPERATIVEL assess the resectability of liver metastases by
ultrasound imaging?
Adjuvant Chemotherapy
1. Following potentially curative resection forCOLORECTALCARCINOMA, was any
ADJUVANT chemotherapeutic treatment given routinely in 19917
If yes, which drugs did you administer, and by which route?
2. Following potentially curative partial LIVER resection, was any ADJUVANT
chemotherapeutic treatment given routinely in 1991?
If yes, which drugs did you administer, and by which route?
Chemotherapy
1. In how many patients were IRRESECTABLE liver metastases detected in 1991?
2. If irresectable liver metastases were detected, what was your policy regarding
chemotherapy in 1991?
a. No further treatment
b. Systemic I.V. chemotherapy
c. Lgcal (intra-arterial or intraportal) chemotherapy
d. Other treatment (please specify)
pts.
pts.
Yes
No
Yes
U]No
Yes
U]No
pts.
3. How many of these patients were actually treated with chemotherapy in 1991? pts.